St. Jude Medical / Abbott: Portico™ Valve - (CE)

Transcatheter aortic valve devices

The Portico™ Transcatheter Aortic Heart Valve offers outstanding control and accuracy for optimal patient outcomes with low rates of post-procedure pacemaker implantations, complications and paravalvular leak (PVL). The valve’s unique delivery system provides controlled deployment for greater accuracy and precise placement. The Portico™ transcatheter aortic heart valve is part of St Jude Medical's transcatheter valve replacement portfolio.

Portico™ Valve introduction

The Portico™ transcatheter aortic heart valve is designed to be implanted in the native aortic heart valve without open-heart surgery and without concomitant surgical removal of the failed native valve. The valve is implanted using the Portico™ transfemoral delivery system.

Studies show that the Portico™ aortic valve has low rates of pacemaker implantation and complications and comparable PVL when compared to second-generation transcatheter aortic valve implantation (TAVI) valves.

Portico™ aortic valve

Figure 63. Portico aortic valve


Portico™ aortic valve

Figure 64. Portico aortic valve


Portico™ aortic valve

Figure 65. Portico aortic valve


Portico™ Valve animation

Portico™ Valve animation


General characteristics:






Bovine pericardium

Valve size (mm)

23 mm, 25 mm, 27 mm, 29 mm

Delivery system diameter - 1 [figure=66 chapter=3] / 2 [figure=67 chapter=3] / 3 [figure=68 chapter=3] / 4 [figure=69 chapter=3]

18 Fr [figure=70 chapter=3] for 23 mm and 27mm
19 Fr [figure=70 chapter=3] for 27 mm and 29 mm

Implantation access

Transfemoral [video=16 chapter=3], transapical, transaortic, subclavian



Retrievable after being fully deployed


Additional cuff to reduce AR


Anchoring mechanism

By design

Tactile feedback during deployment


Large stent cell design


Markers to facilitate deployment


Motorised delivery system


Anticalcification technology


CE mark status: 19/11/2012 (transfemoral)


Special features:

  • Low valve height allowing for sealing without the valve extending deep into the LVOT to minimise conduction interference
  • The large cells in the annulus section of the stent are designed to minimise the risk of PV leak
  • Leaflet geometry designed to function optimally in both round movie 17 [video=17 chapter=3] and elliptical configurations movie 26 [video=26 chapter=3]
  • Transfemoral delivery system and 23 mm and 25 mm valve CE approved. Transapical, Transaortic and Subclavian systems and 27 mm, 29 mm are investigational devices. Not available for sale in the U.S.A.


Angiogram implantation:


Supported by